Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Oral Presentation# OR36-1 Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at ...